Chris MacDonald

Chris MacDonald

InvestorPlace Contributor

Chris MacDonald is an MBA (finance) graduate with extensive experience covering small-, mid- and large-cap companies in the U.S. and Canadian markets. Chris is interesting in uncovering long-term and deep-value opportunities for investors based on principles from the Graham-Buffett school of thought, and looks forward to bringing investors a unique fundamental-based perspective on opportunities available in today’s challenging investing environment.

His experience as a financial analyst in the past, coupled with his fervor for finding undervalued growth opportunities, contribute to his conservative, long-term investing perspective.

Recent Articles

Chinese Fintech Stocks: What’s Going on With FUTU, TIGR Stocks Today?

By Chris MacDonald, InvestorPlace Contributor

Today, investors in Chinese fintech stocks are bleeding red, as both FUTU stock and TIGR stock see dramatic declines this afternoon.

Ginkgo Bioworks Price Predictions: Why One Analyst Thinks Hard-Hit DNA Stock Can Hit $14.50

By Chris MacDonald, InvestorPlace Contributor

Today, a bullish analyst price target placed on Ginkgo Bioworks has sent DNA stock on a nice ride as investors pile into this growth play.

PAVM Stock: One Big Reason Why PAVmed Is Plunging Today

By Chris MacDonald, InvestorPlace Contributor

Today, a relatively disappointing start to trading for a PAVmed subsidiary, Lucid Diagnostics, is driving some bearish price action.

LUCD Stock IPO: 7 Things to Know as Lucid Diagnostics Starts Trading Today

By Chris MacDonald, InvestorPlace Contributor

Unfortunately, today is a very red day for investors who got in on the recent LUCD stock IPO, with shares of this stock down more than 17%.

Cardano Price Predictions: Can the ADA Crypto Really Hit $20 By Year End?

By Chris MacDonald, InvestorPlace Contributor

Here's what investors may want to know about some of the various Cardano price predictions that provide a bullish outlook for this crypto.

CGC Stock Alert: 7 Things to Know About the Latest Canopy Growth Deal

By Chris MacDonald, InvestorPlace Contributor

Today, investors in Canopy Growth and CGC stock are buying into this cannabis player heavily as the company announced a key acquisition.

OCGN Stock: One Big Reason Why Ocugen Is Climbing Today

By Chris MacDonald, InvestorPlace Contributor

Covid-19 vaccine play Ocugen is seeing impressive investor interest today, with OCGN stock seeing double-digit gains at the time of writing.

#AMCSqueeze: What Is Going on With AMC Stock Today?

By Chris MacDonald, InvestorPlace Contributor

Recent news that a short seller has exited their position in AMC stock has made AMC go viral on social media platforms today.

GRVI Stock Is Soaring Thanks to This Amazon-Sized Catalyst

By Chris MacDonald, InvestorPlace Contributor

Today, Grove's announcement move to launch a brand targeted at growing the company's e-commerce business has GRVI stock surging.

ORPH Stock Alert: What’s Going on With Red-Hot Orphazyme Today?

By Chris MacDonald, InvestorPlace Contributor

Today, retail investors and traders appear willing to put some big money down on Orphazyme and ORPH stock as a potential short-squeeze play.

Load More